Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Preventor µTBC GmbH is a German biotechnology and drug safety company founded in 1998 by Prof. Dr. Paul Kerth. The company specializes in the development, production, and distribution of rapid and preventive diagnostics, theranostics, and formulation development, with a focus on ophthalmology, immunology, hematology, and cardiology. Key technologies include the Micro Tele BioChip (µTBC) and the Blood Liquid Separation Chip (BLISC), a capillary blood-plasma separation microchip based on physical separation. Preventor µTBC also provides contract research and manufacturing services, including anti-counterfeiting analysis, active ingredient design, bioequivalence testing (using its SuperSol 1000 system), and regulatory expertise. Additionally, the company manufactures and distributes organic formulations and premium animal health products, such as BeneFishial Pet, an anti-inflammatory omega-3 food supplement for cats and dogs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Preventor µTBC.